We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo ...

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

Here are some of the major companies whose stocks moved on the week’s news.

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

U.S. stocks are edging back from their all-time high on Friday as they close out a second straight winning week. The S&P 500 ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...